tbuckley/cabot-search huggingface dataset:
Abstract 18237: Non-invasive Three Dimensional Imaging of Ventricular Arrhythmias: In-procedure Simultaneous Mapping of Ventricular Tachycardia and Premature Ventricular Complexes
Authors: Long Yu, Steve Pogwizd, Hugh T McElderry, Ting Yang, Bin He
Journal: Circulation (2015)

Introduction: Noninvasive activation imaging and the identification of initiation sites or reentrant circuits are highly desirable for aiding catheter ablative treatment of ventricular arrhythmia. While approaches are being developed to image epicardial potential, Cardiac Electrical Sparse Imaging (CESI), a 3-dimensional noninvasive activation imaging technique offers insight into intramural activation. In this study, we report the first clinical study of the CESI technique with in-procedure simultaneous mapping of Ventricular Tachycardia (VT) and Premature Ventricular Complexes (PVCs). Methods: Body surface potential maps (BSPMs) were recorded using 170±9 electrodes in 4 patients (2 males, 2 females, age 53±5) with VT and/or PVC in the EP lab simultaneously with CARTO mapping and ablation. CT or MRI images were obtained for individualized volume conductor modeling. Activation sequences were estimated using CESI upon the 40 isolated PVC or VT beats induced by programmed stimulation or isoproterenol infusion. Imaging results were compared with CARTO map and ablation sites/outcomes. Results: Good concordance was observed between the imaged results and the EP study. A Correlation Coefficient of 0.76±0.04 and Relative Error of 0.22±0.05 were found between the imaged activation sequences and the Local Activation Time maps from CARTO. The imaged initiation sites well co-localized with the ablation outcomes with Localization Error of 8±1.3mm from the last ablation site and 3.3±1.7mm from the nearest ablation site. Conclusions: We demonstrate for the first time that the beat-to-beat 3D activation imaging technique CESI can be applied clinically with simultaneous mapping in the EP lab. The noninvasive imaging results are in good agreement with the EP study and catheter ablation outcome. The promising results suggest CESI warrants further investigation and has the potential to become a clinically useful technology guiding ablation procedures in patients.
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.
Authors: Eileen Mary O'Reilly, Devalingam Mahalingam, James M. Roach, Paul Justin Miller, Molly E. Rosano, Silva Krause, Julie Wolf, Keith Flaherty, David P. Ryan
Journal: Journal of Clinical Oncology (2016)

4117 Background: Necuparanib (“necu”) inhibits multiple heparin-binding growth factors, chemokines, and adhesion molecules in nonclinical studies. It is being evaluated in a Phase 1/2 trial with nab-paclitaxel (nabP) + gemcitabine (gem) in patients (pts) with metastatic pancreatic cancer. Updated Phase 1 safety/pharmacokinetic (PK)/pharmacodynamic (PD) data are provided. Methods: Necu was given as daily escalating s.c. doses in combination with i.v. 125 mg/m2 nabP and 1000 mg/m2 gem (Days 1, 8, 15 of each 28-day cycle). The necu start dose was 0.5 mg/kg and was escalated until the maximum tolerated dose was determined (which was 5 mg/kg). The protocol was amended to include nabP after 2 necu + gem cohorts were completed. Results: 39 pts in 7 cohorts (0.5 and 1 mg/kg + gem; 1, 2, 4, 6, and 5 mg/kg + nabP + gem) received necu. No new safety issues have been observed in this Phase 1 trial over the past year and no increase in known AEs of chemotherapy across doses was observed. Exposure to necu was observed starting at 2 mg/kg. Release of heparin-binding proteins (e.g. HGF, a PD marker) from heparan sulfate stores increased with dose and plateaued at 4-5 mg/kg. 3 (8%) pts remain alive; 19 (49%) pts have lived > 1 year, 8 (21%) > 1.5 years, and 4 (10%) > 2 years; 33.7 months is the longest survival to date. 16 pts treated with necu + nabP + gem completed Cycle 1 and had ≥ 1 scan on treatment; 8 (50%) achieved RECIST partial response and 6 (38%) achieved stable disease, for a disease control rate of 14/16 (88%); median overall survival (OS) in this subset was 16.0 months. Median OS of patients treated with ≥ 1 dose of necu + nabP + gem (n = 24) was 12.4 months. Of 15 CA19.9 evaluable pts, 15 (100%) had > 20%, 14 (93%) had > 50%, and 7 (47%) had > 90% decreases from baseline. Conclusions: Acceptable tolerability and encouraging signals of activity continue to be observed with the combination, which is being further evaluated in an ongoing randomized, double-blind, Phase 2 trial. Clinical trial information: NCT01621243.
Avatars Identify Genetic Sources of Drug Response
Journal: Cancer Discovery (2015)

Abstract Using mouse avatars implanted with liver metastases of late-stage colorectal cancers, researchers uncovered mutations in five genes—ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1—that seem to promote cetuximab resistance. They also found that mutations in IRS2 may boost tumors' vulnerability to anti-EGFR therapy and tested specific therapies in the mice to gauge the drugs' effectiveness.
Conjoined twins
Authors: G R Hervey
Journal: Journal of the Royal Society of Medicine (2005)

Erdheim-Chester diseaseDr Lee and his colleagues (April 2005 JRSM 1 ) describe a case of renal failure in which the radiographic appearance of bone pointed to Erdheim-Chester disease, a histiocytosis.Among the organs affected in this condition they mention pericardium.We think it important to emphasize the frequency with which heart, pericardium and great vessels are affected.Recording 6 new patients with cardiovascular involvement, Haroche et al. 2 have reviewed all 178 reported cases of Erdheim-Chester disease.56% had periaortic fibrosis, 44% pericardial infiltration and/or effusions and 31% myocardial infiltration.Interestingly, 6 patients had a right atrial myxoma.Of the 58 patients with follow-up data, 31% died from cardiovascular complications.
Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation
Authors: Thiyagaragan M. Achariyar, Baoman Li, Weiguo Peng, Philip B. Verghese, Yang Shi, Evan McConnell, Abdellatif Benraiss, Tristan Kasper, Wei Song, Takahiro Takano, David M. Holtzman, Maiken Nedergaard, Rashid Deane
Journal: Molecular Neurodegeneration (2017)
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
Journal: Journal of Clinical Oncology (1997)

PURPOSE The role of 5-HT3 receptor antagonists in the prevention of chemotherapy-induced delayed emesis is controversial. We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients. PATIENTS AND METHODS Three hundred twenty-two patients who had been given &gt; or = 50 mg/m2 of cisplatin were randomly assigned to receive, from days 2 to 4 after chemotherapy, oral ondansetron (8 mg twice daily) or oral metoclopramide (20 mg every 6 hours), both associated with intramuscular dexamethasone (8 mg twice on days 2 and 3, and 4 mg twice on day 4). Patients received the same intravenous prophylaxis for acute emesis: ondansetron 8 mg and dexamethasone 20 mg. Nausea and vomiting were assessed daily until day 6 after chemotherapy. RESULTS According to the intention-to-treat principle, 318 patients were assessable. Known prognostic factors were similar in the two treatment groups. Complete protection from delayed vomiting and nausea was achieved by 62.0% and 43.7% of patients treated with ondansetron and by 60.0% and 53.7% of those receiving metoclopramide (no significant differences). Patients who vomited in the first 24 hours achieved the lowest complete protection from delayed emesis. In these patients, ondansetron offered better complete protection from vomiting than metoclopramide (28.6% v 3.8%, P &lt; .05). Both treatments were well tolerated. CONCLUSION The two treatments offer similar protection from delayed emesis, although ondansetron plus dexamethasone may be preferred in patients who suffer from acute vomiting. Optimal control of acute emesis is essential to achieve good protection from delayed nausea and vomiting, irrespective of the antiemetic treatment received.
THE REPORT OF THE COMMITTEE ON ORGANIZATION.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medicine's ethical responsibilities
Authors: R. B. Roth
Journal: JAMA (1971)

An interesting question arises at formal conferences, where the nature of physician activities is discussed under the general heading of ethics. Time was when the physician graduated from medical school, gave testimony to his competence in passing assorted examinations for licensure or recognition as a specialist, and then devoted himself rather exclusively to the business of exercising his talents and his skills on behalf of those who came to him as patients. So long as he dealt with his patients equitably and ministered to them with competence he was regarded as a paragon of ethical probity. Today it would appear that such professional isolationism is not so completely defensible. There is the implication that, when one undertakes a career in medicine, one, at the same time, assumes responsibilities extending beyond a one-to-one physician-patient relationship. The interesting question is this: to what extent is this implication true? In certain circumscribed
A PLEA FOR PATHOLOGIC PHYSIOLOGY.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of coagulation and fibrinolytic parameters with brachial artery flow mediated dilation and carotid artery intima-media thickness: Indicator of patients at high risk for coronary artery disease Tomoo Furumoto, Satoshi Fujii, Naotaka Saito, Taisei Mikami, Kazushi Urasawa, Akira Kitabatake. Hokkaido University Cardiology, Sapporo, Japan
Journal: Journal of the American College of Cardiology (2001)
Gli Apparecchi Ortopedici.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hyperoleon
Authors: Donato Colantuono, Eric Souied
Journal: New England Journal of Medicine (2020)

A 69-year-old man who had undergone cataract surgery and a vitrectomy of the right eye 3 years earlier presented to the ophthalmology clinic. Examination of the right eye revealed a layer of emulsified silicone oil in the superior anterior chamber, known as a hyperoleon.
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Authors: Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin, Matthew D Hellmann, David A Barron, Alison M Schram, Meera Hameed, Snjezana Dogan, Dara S Ross, Jaclyn F Hechtman, Deborah F DeLair, JinJuan Yao, Diana L Mandelker, Donavan T Cheng, Raghu Chandramohan, Abhinita S Mohanty, Ryan N Ptashkin, Gowtham Jayakumaran, Meera Prasad, Mustafa H Syed, Anoop Balakrishnan Rema, Zhen Y Liu, Khedoudja Nafa, Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona J Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry A Mullaney, Hikmat Al-Ahmadie, Efsevia Vakiani, Adam A Abeshouse, Alexander V Penson, Philip Jonsson, Niedzica Camacho, Matthew T Chang, Helen H Won, Benjamin E Gross, Ritika Kundra, Zachary J Heins, Hsiao-Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B Thomas, Stuart M Gardos, Dalicia N Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R Feldman, Mrinal M Gounder, A Ari Hakimi, James J Harding, Gopa Iyer, Yelena Y Janjigian, Emmet J Jordan, Ciara M Kelly, Maeve A Lowery, Luc G T Morris, Antonio M Omuro, Nitya Raj, Pedram Razavi, Alexander N Shoushtari, Neerav Shukla, Tara E Soumerai, Anna M Varghese, Rona Yaeger, Jonathan Coleman, Bernard Bochner, Gregory J Riely, Leonard B Saltz, Howard I Scher, Paul J Sabbatini, Mark E Robson, David S Klimstra, Barry S Taylor, Jose Baselga, Nikolaus Schultz, David M Hyman, Maria E Arcila, David B Solit, Marc Ladanyi, Michael F Berger
Journal: Nature Medicine (2017)
Highlights
Authors: Raymond Roos
Journal: JAMA Neurology (2016)

Melo and colleagues describe the prenatal evolution and perinatal outcomes of 11 neonates who had developmental abnormalities and neurological damage associated with Zika virus (ZIKV) infection in Brazil.They observed 11 infants with congenital ZIKV infection from gestation to 6 months in the state of Paraíba, Brazil.Combined fi ndings from clinical, laboratory, imaging, and pathological examinations provided a more complete picture of the severe damage and developmental abnormalities caused by ZIKV infection than has been previously reported.
Leads from the MMWR. Update: human immunodeficiency virus infections in health-care workers exposed to blood of infected patients
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disinfecting ventilators.
Journal: BMJ (1973)

therapy for several years.416J.H. Burchenal,17 from a world- wide survey of long-term survivors in acute leukaemia, found that 50% of those who had survived five years went on to survive 15 years, generally being off all chemotherapy for the latter part of this time, none relapsing after eight years of continuous remission.If this finding can be applied to more recent series, in which 40 to 50% of patients are expected to reach five years without recurrence, then 20 to 25% should reach 15 years, which would surely indicate cure.
Alcohol and the future of Native Americans
Authors: K. Prager
Journal: JAMA (1993)

<h3>In Reply.</h3> —Dr Prager's response to my Editorial on hypothermia deaths and pedestrian motor vehicle accidents among American Indians in the Southwest highlights some important issues. He states that we need "bold-thinking Native Americans [the preferred term is<i>American Indians</i>among many American Indians and American Indian scholars] who can deal with the root causes of alcoholism by finding ways to strengthen their own traditional and rich cultures while incorporating what they feel is the best of all American civilization." Prager may be interested to know that many tribes and tribal members have been doing this for years and continue to strengthen their culture through tribal sovereignty. In fact, the Cheyenne River Sioux Tribe where Prager briefly worked has been very aggressive in its efforts to gain greater control and regulation over the sale and distribution of alcohol. The Cheyenne River Indian Reservation demonstrates that the exercise of tribal sovereignty
Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver
Authors: L Bayon
Journal: Hepatology (1996)

Metastasis to the liver is a common event in clinical oncology. Blood-borne tumor cells (TCs) arriving to the liver sinusoids run into a special vascular bed. The lining of liver sinusoids is shared by Kupffer cells (KCs) and endothelial cells. KCs, liver-fixed macrophages, are responsible for detection and removal of “non-self” particles. To investigate their role in arresting blood-borne TCs and controlling tumor growth, we injected a syngeneic colon carcinoma cell line into a mesenteric vein of two groups of rats; one group was without Kupffer cells and the other normal controls. We removed the liver of these animals at different time intervals and performed immunohistochemical analysis with monoclonal antibodies (MoAbs) against our tumor cell line, three macrophage subpopulations, natural killer cells, and B and T lymphocytes. Additionally, we showed in vitro spontaneous cytotoxicity of KCs against our tumor cell line. Results suggest that KCs play a relevant role in arresting circulating TCs at the liver sinusoid, although it is limited to a small number of malignant cells. They also seem to play a major role in clearing neoplastic cells from the liver parenchyma, in controlling tumor growth in the very early stages of metastatic development, and in modulating the host immune response to cancer cells.
Practice guidelines and practicing medicine. Are they compatible?
Authors: R. H. Brook
Journal: JAMA (1989)

Various factors, including increased financial pressures on the health system, the rapidity of the introduction of technology, and data showing high levels of inappropriate care, will coalesce into a movement that will yield practice guidelines. If the guidelines are developed with the aid of the best methods and if they are applied constructively, then the twin goals of increased health of the American public and physician satisfaction can be achieved. (<i>JAMA</i>. 1989;262:3027-3030)